Lipid Nanoparticle Composition for In Vivo HSC Genome Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for genome editing in hematopoietic stem cells, such as electroporation, require ex vivo processes that impose a significant burden on patients and lack safety and efficiency, necessitating a less invasive and more efficient in vivo approach.
Innovation Solution
A drug delivery system using a lipid nanoparticle encapsulating a genome editing molecule, composed of specific lipid ratios, facilitates in vivo genome editing in hematopoietic stem cells by enabling efficient uptake and delivery of the molecule without the need for antibodies or receptors, utilizing a lipid composition that includes FFT-10 and FFT-20 lipids with a cationic lipid content of 60 mol% or less.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If electroporation method is used for gene introduction, then gene can be introduced into hematopoietic stem cells, but the process requires ex vivo treatment which imposes great burden on patient
Solution Approach 1:
The patent uses a lipid nanoparticle as an intermediary carrier to deliver the genome editing molecule (Cas9 mRNA and guide RNA) into hematopoietic stem cells. This lipid nanoparticle mediator enables in vivo delivery without requiring ex vivo cell collection, manipulation, and retransplantation, thereby resolving the contradiction between effective gene introduction and patient burden.
2Reliability
If viral vectors or lipofection methods are used for genome editing, then gene delivery can be achieved, but safety and efficiency are insufficient
Solution Approach 1:
The patent optimizes the lipid composition parameters of the nanoparticle, specifically setting the cationic lipid content to 60 mol% or less and incorporating specific lipid ratios (FFT-10 and FFT-20), to achieve both high delivery efficiency and improved safety by avoiding the risks associated with viral vectors and traditional lipofection methods.
Solution Approach 2:
The patent employs a composite lipid nanoparticle system comprising multiple lipid components including cationic lipids, neutral lipids, and specific formulations (FFT-10 and FFT-20) to achieve synergistic effects that improve both delivery efficiency and safety compared to single-component systems like traditional lipofection.
3Productivity
If high cationic lipid content is used in lipid nanoparticle, then gene delivery efficiency may improve, but uptake by non-target cells increases
Solution Approach 1:
The patent precisely controls the cationic lipid content parameter at 60 mol% or less to balance delivery efficiency with specificity. This parameter optimization prevents excessive electrostatic interactions that would cause non-target cell uptake while maintaining sufficient efficiency for therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system allows for safe and efficient genome editing in hematopoietic stem cells in vivo, reducing patient burden and improving delivery efficiency compared to viral vectors and lipofection methods, while minimizing uptake by non-target cells.
Implementation Method 1
a lipid nanoparticle encapsulating the genome editing molecule, in which the lipid nanoparticle includes a lipid membrane having a lumen
Implementation Method 2
the lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20), wherein the second lipid is contained in a larger amount than the first lipid, and a total amount of the first lipid and the second lipid is 40 mol % or less, and a total amount of the cationic lipid is 60 mol % or less
Data Source
AI summary
A drug for genetic modification according to an embodiment is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule and a lipid nanoparticle encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol % or less, and the total amount of the cationic lipid is 60 mol % or less.